Skip to main content
    M

    Marker Therapeutics Inc (MRKR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.83
    -0.04 (-4.76%)

    Market Cap: $14.51M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Marker Therapeutics Inc (MRKR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Marker Therapeutics are Plus Therapeutics (PSTV), Tempest Therapeutics (TPST) and Moleculin Biotech (MBRX). By market cap, Marker Therapeutics ranks 5th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.

    Peer Comparison

    MRKR's revenue growth of -51.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Marker Therapeutics (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    Plus Therapeutics Inc (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Intensity Therapeutics, Inc. Common stock (INTS)$10.17MN/AN/A0.0%N/A0.0%0.00%
    Estrella Immunopharma Inc. (ESLA)$22.36MN/AN/A0.0%N/A0.0%0.00%
    Tscan Therapeutics Inc (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    Chemomab Therapeutics Ltd DRC (CMMB)$12.31MN/AN/A0.0%N/A0.0%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    Seres Therapeutics Inc (MCRB)$14.27MN/A6.6x0.0%N/A68.9%0.00%
    Transcode Therapeutics Inc (RNAZ)$22.35MN/AN/A0.0%-412.7%0.0%0.00%
    GT Biopharma Inc (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    Peer median$11.60MN/A5.1x0.0%-412.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Marker Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Plus Therapeutics Inc (PSTV)
    Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing...
    PSTV competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Intensity Therapeutics, Inc. Common stock (INTS)
    Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems.
    INTS competitors
    Estrella Immunopharma Inc. (ESLA)
    Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
    ESLA competitors
    Tscan Therapeutics Inc (TCRX)
    Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor...
    TCRX competitors
    Chemomab Therapeutics Ltd DRC (CMMB)
    Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases.
    CMMB competitors
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors
    Seres Therapeutics Inc (MCRB)
    Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally...
    MCRB competitors
    Transcode Therapeutics Inc (RNAZ)
    TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic...
    RNAZ competitors
    GT Biopharma Inc (GTBP)
    GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its...
    GTBP competitors

    Frequently Asked Questions About MRKR

    Who are Marker Therapeutics' main competitors?

    The companies most similar to Marker Therapeutics include Plus Therapeutics (PSTV), Tempest Therapeutics (TPST), Moleculin Biotech (MBRX), CytoMed Therapeutics Limited Ordinary Shares (GDTC) and Intensity Therapeutics, Inc. Common stock (INTS), listed from the closest match.

    Who is Marker Therapeutics' biggest competitor?

    Plus Therapeutics (PSTV) is both the largest of the similar companies at $26.64M and the closest match by business profile, size, sector and industry.

    How does MRKR stock compare with its competitors?

    MRKR's P/S is 14.5x against a peer median of 5.1x; its net margin is -245.5% against a peer median of 0.0%.

    Which of Marker Therapeutics' competitors pays a higher dividend?

    Marker Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Marker Therapeutics bigger than its competitors?

    No. Marker Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.